Patent foramen ovale closure in young Patients with cryptogenic stroke: a case series and follow up from Saudi population. by Albakr, Aishah et al.
Pakistan Journal of
Neurological Sciences (PJNS)
Volume 14 | Issue 2 Article 7
6-2019
Patent foramen ovale closure in young Patients with
cryptogenic stroke: a case series and follow up from
Saudi population.
Aishah Albakr
Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia
Noman Ishaque
Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia.
Rizwana Shahid
Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia.
Alaa Jamal Al Obaidli
Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia
Noora Waleed Alayyaf
Imam Abdulrahman Bin Faisal University, Dammam, Kingdom of Saudi Arabia.
See next page for additional authors
Follow this and additional works at: https://ecommons.aku.edu/pjns
Part of the Neurology Commons
Recommended Citation
Albakr, Aishah; Ishaque, Noman; Shahid, Rizwana; Al Obaidli, Alaa Jamal; Waleed Alayyaf, Noora; AlMansoori, Mohammed; and
Saleh Al Amri, Sarah Ali (2019) "Patent foramen ovale closure in young Patients with cryptogenic stroke: a case series and follow up
from Saudi population.," Pakistan Journal of Neurological Sciences (PJNS): Vol. 14 : Iss. 2 , Article 7.
Available at: https://ecommons.aku.edu/pjns/vol14/iss2/7
Patent foramen ovale closure in young Patients with cryptogenic stroke: a
case series and follow up from Saudi population.
Authors
Aishah Albakr, Noman Ishaque, Rizwana Shahid, Alaa Jamal Al Obaidli, Noora Waleed Alayyaf, Mohammed
AlMansoori, and Sarah Ali Saleh Al Amri
This original article is available in Pakistan Journal of Neurological Sciences (PJNS): https://ecommons.aku.edu/pjns/vol14/iss2/7
O R I G I N A L  A R T I C L E
INTRODUCTION: One quarter of cerebral infarctions is 
cryptogenic and Patent Foramen Ovale (PFO) is highly 
prevalent in such patients especially those less than 50 
years. PFO is a persistent passage between two atria 
and is visualized in about 25% of general population. 
PFO is considered to cause stroke either by paradoxical 
embolism or by in situ thrombus formation. Recently 
published three randomized trials have demonstrated 
efficacy of PFO closure in preventing stroke recurrence 
in patients with PFO and cryptogenic cerebral 
infarction. We report four cases of cryptogenic cerebral 
infarction in young patients in whom PFO was found 




43 years old gentleman, smoker, no known medical 
illness reported to emergency department complaining 
of weakness of left side of body. His neurologic 
examination revealed decreased sensation on left side 
of body. MRI head showed acute infarction of right 
thalamocapsular junction. CT angiogram of head and 
neck as well as 24 hour holter monitoring were 
unremarkable .His HbA1c was normal and lipid profile 
revealed high cholesterol and LDL. His work up for 
thrombophilia as well as autoimmune disease was 
negative. His trans-esophageal echo showed Patent 
Foramen Ovale. During hospitalization, his blood 
pressure readings were within normal ranges. His PFO 
was closed one week later without any complication. 
He was discharged on dual antiplatelet therapy and 
statin. He followed up in clinic for 14 months without 
new neurologic symptoms or signs.
Case 2:
36 years old gentleman, smoker, no known medical 
illness presented with complaint of left sided body 
weakness. His neurologic examination revealed mild 
weakness of left side involving face, arm and leg. His 
MRI head showed acute infarction involving right 
periventricular area. MR angiogram of head and neck 
was unremarkable. His ECG showed normal sinus 
rhythm.  His lipid profile and HbA1c were normal. His 
thrombophilic work up as well as autoimmune work up 
was negative. His trans-esophageal echo showed PFO 
with mobile interatrial septum. During hospitalization, 
his blood pressure readings were within normal ranges. 
He underwent closure of PFO 10 days later without any 
complication. He was discharged on dual antiplatelet 
therapy for 6 months and statin. He was followed up in 




44 years old gentleman, tobacco chewer, no previous 
known medical illness came to emergency department 
complaining of  weakness of right side of body. His 
neurologic examination was positive for ataxia of right 
upper and lower limbs and mild right lower extremity 
weakness. His head MRI showed acute infarction of 
posterior limb of left internal capsule. MR angiograms 
of head and neck as well as 24 hour holter monitoring 
were unremarkable. His HbA1c was normal and lipid 
profile showed high cholesterol and LDL. His 
autoimmune works up as well as thrombophilic work up 
were negative. His transesophageal echo showed PFO. 
He was normotensive. He underwent percutaneous 
closure of PFO. He was discharged on dual antiplatelet 
therapy for 6 months and statin. He followed in clinic 
for 12 months without recurrence of symptoms.
Case 4:
44 years old gentleman, non-smoker, hypertensive 
presented to outpatient clinic with sudden onset left 
sided weakness lasting 30 minutes. His neurologic 
examination was unremarkable at time of presentation. 
His non contrast CT scan of head was unremarkable. 
His ultrasound Doppler of carotids and ECG were 
unremarkable. MR or CT angiogram was not done. His 
HbA1c was normal and lipid profile showed high LDL. 
His echo showed Patent Foramen Ovale. He was 
treated with dual antiplatelet therapy, statin and 
anti-hypertensive medication. 2 weeks later, he 
underwent percutaneous PFO closure and was kept on 
dual antiplatelet therapy for 6 months then switched to 
clopidogrel. He was followed up in clinic for 24 months 
without any complication. 
Figure 1. a) Diffusion weighted imaging (DWI) and 
adjusted Diffusion Coefficient (ADC) of case 1, showing 
acute infraction of right thalamo-capsular junction/ b) 
Diffusion weighted imaging (DWI) and adjusted 
diffusion coefficient (ADC) of case 2, showing acute 
infraction of right periventricular region. c) Diffusion 
weighted imaging (DWI) and adjusted diffusion 
coefficient (ADC) of caes 3, shwoing acute infraction of 
posterior limb of left internal capsule.
Discussion
Cryptogenic strokes comprise one fourth of all ischemic 
strokes and most of them are embolic in nature. 
Case-control studies have demonstrated that PFO is 
more frequent in subjects with cryptogenic cerebral 
infarction than in age-matched subjects without 
cerebral infarction.1 The foramen ovale is passage that 
exists in the wall between the two atria of every human 
fetus. It normally shuts during infancy but in 
approximately one quarter of general population it 
remains patent2.In an autopsy based study, overall 
incidence of PFO was 27%  and incidence decreased 
with increasing age whereas size of defect increased 
with increased age.3In population based study 
Meissner et al have reported that 24.3% of their 
sample population had PFO.4 The correlation of PFO 
with stroke was first described by Cohnheim in year 
1877.5Meta-analysis of case-control studies has 
demonstrated that likelihood of finding PFO was twice 
in subjects with cerebral infarction as compared to 
control subjects and this association was three times 
more likely in group of subjects with cryptogenic 
cerebral infarction whose ages  were less than 55 
years.6Similar findings have been reported in another 
meta-analysis of case-control studies demonstrating 
that likelihood of finding PFO in patients with stroke of 
unknown etiology was three times higher as compared 
to age matched control subjects and it increased to 
fivefold in patients of young age group with cryptogenic 
cerebral infarction.7 Prevalence of PFO in subjects with 
cryptogenic stroke reaches up to 34% to 40%.7,8 
Annual  risk of stroke recurrence in patients with PFO 
has been reported to be ranging from 2% over three 
year follow up duration to as high as 12.5% at 3 years 
follow up in high risk patients.9-13 Two possible 
mechanisms have been hypothesized by which PFO can 
cause stroke, one is susceptibility of such patients to 
atrial arrhythmias with thrombus formation and other is 
paradoxical embolization.14 Likelihood that PFO can be 
cause of stroke increases as patient’s age decreases 
as well as if conventional risk factors for stroke are 
absent.15 Younger patients in whom usual risk factors 
for stroke are not found, such subjects are much more 
likely to have PFO than those patients with usual risk 
factors. Kent at al suggested 10-point Risk of 
Paradoxical Embolism score (RoPE score) to divide 
patients with cryptogenic stroke and PFO into high or 
low likelihood proposing that PFO can be cause of 
stroke or is incidental finding.16 This score uses 
patient’s age, cortical infarction on neuroimaging and 
conventional risk factors of stroke. Higher the RopE 
score, higher likelihood that PFO can be cause of 
stroke. Increased use of saline contrast TEE has 
increased the frequency of detection of PFO in stroke 
patients.Three randomized trials published previously 
addressing hypothesis that PFO closure is better than 
medical therapy in secondary stroke prevention came 
out to be negative.17-19 However, recently published 
three randomized trials addressing similar question 
came out to be positive demonstrating that PFO closure 
is better than medical therapy for secondary stroke 
prevention in patients with stroke of unknown etiology 
and PFO. In a randomized, multicentre trial PFO closure 
along with antiplatelet therapy was found to be 
significantly better for secondary stroke prevention in 
patients with stroke whose stroke was attributed to PFO 
with atrial septal aneurysm or large inter-atrial shunt as 
compared to antiplatelet therapy alone(Hazard 
ratio,0.03;95% confidence interval,0-0.26; 
P<0.001).20Also,in extended follow up for a median 
of 6 years of RESPECT trial cases, recurrence of 
cerebral infarction  was 45% less in patients with 
cryptogenic stroke and PFO for whom PFO closure was 
performed.21 REDUCE trial showed that patients with 
cryptogenic stroke with PFO who underwent FO closure 
had 67% lower risk of recurrent ischemic stroke during 
a median follow up of 3.2 years (HR 0.23%, 95% CI 
0.09 to 0.62; P=0.002).22 All of our cases were less 
than 45 years of age and their routine stroke work up 
including CT/MR angiogram of head and neck, 24 hour 
holter monitor as well as work up for thrombophilia and 
autoimmune diseases was negative. This fits into 
description of cryptogenic stroke. Their 
echocardiograms showed patent formen ovale. As 
discussed above, there is strong association of PFO 
with stroke in such patient population. Therefore, in our 
cases PFO can be considered as likely source of stroke. 
So, PFO closure was performed for our cases for 
secondary stroke prevention. All our cases received 
medical therapy along with PFO closure as was done in 
recently published randomized trials of PFO closure. 
None of our cases had either procedure related 
complication or recurrence of stroke symptoms during 
follow up period ranging from 12 months to 24 months.
 
Conclusion
Patent foramen ovale can be a cause of stroke in young 
patients in whom no other cause of stroke can be found 
on work up. Recent literature has shown efficacy of PFO 
closure in such patient population. Our cases also 
demonstrate that PFO closure can be considered in 
young patients with cryptogenic stroke for secondary 
prevention of stroke.
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ABSTRACT:
One quarter of cerebral infarctions are cryptogenic and most of these patients are young. Patent Foramen Ovale (PFO) 
is found to be more prevalent in young persons with cryptogenic stroke and risk of stroke recurrence in such patients 
ranges from as low as 2% per annum to as high as 12% per annum. Since patients with PFO and cryptogenic stroke 
are young they need more effective ways to reduce risk of stroke recurrence hence percutaneous closure of PFO seems 
reasonable approach to deal with this etiology of stroke in such population. We report four cases of cryptogenic stroke 
in young Saudi patients. PFO closure was performed in all. After closure, none of them developed either recurrence of 
symptoms or any complication on follow up for more than one year.
Conclusion: PFO closure can be considered for preventing stroke recurrence in selected young persons with both 
cryptogenic stroke and PFO.
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his blood pressure readings were within normal ranges. 
He underwent closure of PFO 10 days later without any 
complication. He was discharged on dual antiplatelet 
therapy for 6 months and statin. He was followed up in 




44 years old gentleman, tobacco chewer, no previous 
known medical illness came to emergency department 
complaining of  weakness of right side of body. His 
neurologic examination was positive for ataxia of right 
upper and lower limbs and mild right lower extremity 
weakness. His head MRI showed acute infarction of 
posterior limb of left internal capsule. MR angiograms 
of head and neck as well as 24 hour holter monitoring 
were unremarkable. His HbA1c was normal and lipid 
profile showed high cholesterol and LDL. His 
autoimmune works up as well as thrombophilic work up 
were negative. His transesophageal echo showed PFO. 
He was normotensive. He underwent percutaneous 
closure of PFO. He was discharged on dual antiplatelet 
therapy for 6 months and statin. He followed in clinic 
for 12 months without recurrence of symptoms.
Case 4:
44 years old gentleman, non-smoker, hypertensive 
presented to outpatient clinic with sudden onset left 
sided weakness lasting 30 minutes. His neurologic 
examination was unremarkable at time of presentation. 
His non contrast CT scan of head was unremarkable. 
His ultrasound Doppler of carotids and ECG were 
unremarkable. MR or CT angiogram was not done. His 
HbA1c was normal and lipid profile showed high LDL. 
His echo showed Patent Foramen Ovale. He was 
treated with dual antiplatelet therapy, statin and 
anti-hypertensive medication. 2 weeks later, he 
underwent percutaneous PFO closure and was kept on 
dual antiplatelet therapy for 6 months then switched to 
clopidogrel. He was followed up in clinic for 24 months 
without any complication. 
Figure 1. a) Diffusion weighted imaging (DWI) and 
adjusted Diffusion Coefficient (ADC) of case 1, showing 
acute infraction of right thalamo-capsular junction/ b) 
Diffusion weighted imaging (DWI) and adjusted 
diffusion coefficient (ADC) of case 2, showing acute 
infraction of right periventricular region. c) Diffusion 
weighted imaging (DWI) and adjusted diffusion 
coefficient (ADC) of caes 3, shwoing acute infraction of 
posterior limb of left internal capsule.
Discussion
Cryptogenic strokes comprise one fourth of all ischemic 
strokes and most of them are embolic in nature. 
Case-control studies have demonstrated that PFO is 
more frequent in subjects with cryptogenic cerebral 
infarction than in age-matched subjects without 
cerebral infarction.1 The foramen ovale is passage that 
exists in the wall between the two atria of every human 
fetus. It normally shuts during infancy but in 
approximately one quarter of general population it 
remains patent2.In an autopsy based study, overall 
incidence of PFO was 27%  and incidence decreased 
with increasing age whereas size of defect increased 
with increased age.3In population based study 
Meissner et al have reported that 24.3% of their 
sample population had PFO.4 The correlation of PFO 
with stroke was first described by Cohnheim in year 
1877.5Meta-analysis of case-control studies has 
demonstrated that likelihood of finding PFO was twice 
in subjects with cerebral infarction as compared to 
control subjects and this association was three times 
more likely in group of subjects with cryptogenic 
cerebral infarction whose ages  were less than 55 
years.6Similar findings have been reported in another 
meta-analysis of case-control studies demonstrating 
that likelihood of finding PFO in patients with stroke of 
unknown etiology was three times higher as compared 
to age matched control subjects and it increased to 
fivefold in patients of young age group with cryptogenic 
cerebral infarction.7 Prevalence of PFO in subjects with 
cryptogenic stroke reaches up to 34% to 40%.7,8 
Annual  risk of stroke recurrence in patients with PFO 
has been reported to be ranging from 2% over three 
year follow up duration to as high as 12.5% at 3 years 
follow up in high risk patients.9-13 Two possible 
mechanisms have been hypothesized by which PFO can 
cause stroke, one is susceptibility of such patients to 
atrial arrhythmias with thrombus formation and other is 
paradoxical embolization.14 Likelihood that PFO can be 
cause of stroke increases as patient’s age decreases 
as well as if conventional risk factors for stroke are 
absent.15 Younger patients in whom usual risk factors 
for stroke are not found, such subjects are much more 
likely to have PFO than those patients with usual risk 
factors. Kent at al suggested 10-point Risk of 
Paradoxical Embolism score (RoPE score) to divide 
patients with cryptogenic stroke and PFO into high or 
low likelihood proposing that PFO can be cause of 
stroke or is incidental finding.16 This score uses 
patient’s age, cortical infarction on neuroimaging and 
conventional risk factors of stroke. Higher the RopE 
score, higher likelihood that PFO can be cause of 
stroke. Increased use of saline contrast TEE has 
increased the frequency of detection of PFO in stroke 
patients.Three randomized trials published previously 
addressing hypothesis that PFO closure is better than 
medical therapy in secondary stroke prevention came 
out to be negative.17-19 However, recently published 
three randomized trials addressing similar question 
came out to be positive demonstrating that PFO closure 
is better than medical therapy for secondary stroke 
prevention in patients with stroke of unknown etiology 
and PFO. In a randomized, multicentre trial PFO closure 
along with antiplatelet therapy was found to be 
significantly better for secondary stroke prevention in 
patients with stroke whose stroke was attributed to PFO 
with atrial septal aneurysm or large inter-atrial shunt as 
compared to antiplatelet therapy alone(Hazard 
ratio,0.03;95% confidence interval,0-0.26; 
P<0.001).20Also,in extended follow up for a median 
of 6 years of RESPECT trial cases, recurrence of 
cerebral infarction  was 45% less in patients with 
cryptogenic stroke and PFO for whom PFO closure was 
performed.21 REDUCE trial showed that patients with 
cryptogenic stroke with PFO who underwent FO closure 
had 67% lower risk of recurrent ischemic stroke during 
a median follow up of 3.2 years (HR 0.23%, 95% CI 
0.09 to 0.62; P=0.002).22 All of our cases were less 
than 45 years of age and their routine stroke work up 
including CT/MR angiogram of head and neck, 24 hour 
holter monitor as well as work up for thrombophilia and 
autoimmune diseases was negative. This fits into 
description of cryptogenic stroke. Their 
echocardiograms showed patent formen ovale. As 
discussed above, there is strong association of PFO 
with stroke in such patient population. Therefore, in our 
cases PFO can be considered as likely source of stroke. 
So, PFO closure was performed for our cases for 
secondary stroke prevention. All our cases received 
medical therapy along with PFO closure as was done in 
recently published randomized trials of PFO closure. 
None of our cases had either procedure related 
complication or recurrence of stroke symptoms during 
follow up period ranging from 12 months to 24 months.
 
Conclusion
Patent foramen ovale can be a cause of stroke in young 
patients in whom no other cause of stroke can be found 
on work up. Recent literature has shown efficacy of PFO 
closure in such patient population. Our cases also 
demonstrate that PFO closure can be considered in 
young patients with cryptogenic stroke for secondary 
prevention of stroke.
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his blood pressure readings were within normal ranges. 
He underwent closure of PFO 10 days later without any 
complication. He was discharged on dual antiplatelet 
therapy for 6 months and statin. He was followed up in 




44 years old gentleman, tobacco chewer, no previous 
known medical illness came to emergency department 
complaining of  weakness of right side of body. His 
neurologic examination was positive for ataxia of right 
upper and lower limbs and mild right lower extremity 
weakness. His head MRI showed acute infarction of 
posterior limb of left internal capsule. MR angiograms 
of head and neck as well as 24 hour holter monitoring 
were unremarkable. His HbA1c was normal and lipid 
profile showed high cholesterol and LDL. His 
autoimmune works up as well as thrombophilic work up 
were negative. His transesophageal echo showed PFO. 
He was normotensive. He underwent percutaneous 
closure of PFO. He was discharged on dual antiplatelet 
therapy for 6 months and statin. He followed in clinic 
for 12 months without recurrence of symptoms.
Case 4:
44 years old gentleman, non-smoker, hypertensive 
presented to outpatient clinic with sudden onset left 
sided weakness lasting 30 minutes. His neurologic 
examination was unremarkable at time of presentation. 
His non contrast CT scan of head was unremarkable. 
His ultrasound Doppler of carotids and ECG were 
unremarkable. MR or CT angiogram was not done. His 
HbA1c was normal and lipid profile showed high LDL. 
His echo showed Patent Foramen Ovale. He was 
treated with dual antiplatelet therapy, statin and 
anti-hypertensive medication. 2 weeks later, he 
underwent percutaneous PFO closure and was kept on 
dual antiplatelet therapy for 6 months then switched to 
clopidogrel. He was followed up in clinic for 24 months 
without any complication. 
Figure 1. a) Diffusion weighted imaging (DWI) and 
adjusted Diffusion Coefficient (ADC) of case 1, showing 
acute infraction of right thalamo-capsular junction/ b) 
Diffusion weighted imaging (DWI) and adjusted 
diffusion coefficient (ADC) of case 2, showing acute 
infraction of right periventricular region. c) Diffusion 
weighted imaging (DWI) and adjusted diffusion 
coefficient (ADC) of caes 3, shwoing acute infraction of 
posterior limb of left internal capsule.
Discussion
Cryptogenic strokes comprise one fourth of all ischemic 
strokes and most of them are embolic in nature. 
Case-control studies have demonstrated that PFO is 
more frequent in subjects with cryptogenic cerebral 
infarction than in age-matched subjects without 
cerebral infarction.1 The foramen ovale is passage that 
exists in the wall between the two atria of every human 
fetus. It normally shuts during infancy but in 
approximately one quarter of general population it 
remains patent2.In an autopsy based study, overall 
incidence of PFO was 27%  and incidence decreased 
with increasing age whereas size of defect increased 
with increased age.3In population based study 
Meissner et al have reported that 24.3% of their 
sample population had PFO.4 The correlation of PFO 
with stroke was first described by Cohnheim in year 
1877.5Meta-analysis of case-control studies has 
demonstrated that likelihood of finding PFO was twice 
in subjects with cerebral infarction as compared to 
control subjects and this association was three times 
more likely in group of subjects with cryptogenic 
cerebral infarction whose ages  were less than 55 
years.6Similar findings have been reported in another 
meta-analysis of case-control studies demonstrating 
that likelihood of finding PFO in patients with stroke of 
unknown etiology was three times higher as compared 
to age matched control subjects and it increased to 
fivefold in patients of young age group with cryptogenic 
cerebral infarction.7 Prevalence of PFO in subjects with 
cryptogenic stroke reaches up to 34% to 40%.7,8 
Annual  risk of stroke recurrence in patients with PFO 
has been reported to be ranging from 2% over three 
year follow up duration to as high as 12.5% at 3 years 
follow up in high risk patients.9-13 Two possible 
mechanisms have been hypothesized by which PFO can 
cause stroke, one is susceptibility of such patients to 
atrial arrhythmias with thrombus formation and other is 
paradoxical embolization.14 Likelihood that PFO can be 
cause of stroke increases as patient’s age decreases 
as well as if conventional risk factors for stroke are 
absent.15 Younger patients in whom usual risk factors 
for stroke are not found, such subjects are much more 
likely to have PFO than those patients with usual risk 
factors. Kent at al suggested 10-point Risk of 
Paradoxical Embolism score (RoPE score) to divide 
patients with cryptogenic stroke and PFO into high or 
low likelihood proposing that PFO can be cause of 
stroke or is incidental finding.16 This score uses 
patient’s age, cortical infarction on neuroimaging and 
conventional risk factors of stroke. Higher the RopE 
score, higher likelihood that PFO can be cause of 
stroke. Increased use of saline contrast TEE has 
increased the frequency of detection of PFO in stroke 
patients.Three randomized trials published previously 
addressing hypothesis that PFO closure is better than 
medical therapy in secondary stroke prevention came 
out to be negative.17-19 However, recently published 
three randomized trials addressing similar question 
came out to be positive demonstrating that PFO closure 
is better than medical therapy for secondary stroke 
prevention in patients with stroke of unknown etiology 
and PFO. In a randomized, multicentre trial PFO closure 
along with antiplatelet therapy was found to be 
significantly better for secondary stroke prevention in 
patients with stroke whose stroke was attributed to PFO 
with atrial septal aneurysm or large inter-atrial shunt as 
compared to antiplatelet therapy alone(Hazard 
ratio,0.03;95% confidence interval,0-0.26; 
P<0.001).20Also,in extended follow up for a median 
of 6 years of RESPECT trial cases, recurrence of 
cerebral infarction  was 45% less in patients with 
cryptogenic stroke and PFO for whom PFO closure was 
performed.21 REDUCE trial showed that patients with 
cryptogenic stroke with PFO who underwent FO closure 
had 67% lower risk of recurrent ischemic stroke during 
a median follow up of 3.2 years (HR 0.23%, 95% CI 
0.09 to 0.62; P=0.002).22 All of our cases were less 
than 45 years of age and their routine stroke work up 
including CT/MR angiogram of head and neck, 24 hour 
holter monitor as well as work up for thrombophilia and 
autoimmune diseases was negative. This fits into 
description of cryptogenic stroke. Their 
echocardiograms showed patent formen ovale. As 
discussed above, there is strong association of PFO 
with stroke in such patient population. Therefore, in our 
cases PFO can be considered as likely source of stroke. 
So, PFO closure was performed for our cases for 
secondary stroke prevention. All our cases received 
medical therapy along with PFO closure as was done in 
recently published randomized trials of PFO closure. 
None of our cases had either procedure related 
complication or recurrence of stroke symptoms during 
follow up period ranging from 12 months to 24 months.
 
Conclusion
Patent foramen ovale can be a cause of stroke in young 
patients in whom no other cause of stroke can be found 
on work up. Recent literature has shown efficacy of PFO 
closure in such patient population. Our cases also 
demonstrate that PFO closure can be considered in 
young patients with cryptogenic stroke for secondary 
prevention of stroke.
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his blood pressure readings were within normal ranges. 
He underwent closure of PFO 10 days later without any 
complication. He was discharged on dual antiplatelet 
therapy for 6 months and statin. He was followed up in 




44 years old gentleman, tobacco chewer, no previous 
known medical illness came to emergency department 
complaining of  weakness of right side of body. His 
neurologic examination was positive for ataxia of right 
upper and lower limbs and mild right lower extremity 
weakness. His head MRI showed acute infarction of 
posterior limb of left internal capsule. MR angiograms 
of head and neck as well as 24 hour holter monitoring 
were unremarkable. His HbA1c was normal and lipid 
profile showed high cholesterol and LDL. His 
autoimmune works up as well as thrombophilic work up 
were negative. His transesophageal echo showed PFO. 
He was normotensive. He underwent percutaneous 
closure of PFO. He was discharged on dual antiplatelet 
therapy for 6 months and statin. He followed in clinic 
for 12 months without recurrence of symptoms.
Case 4:
44 years old gentleman, non-smoker, hypertensive 
presented to outpatient clinic with sudden onset left 
sided weakness lasting 30 minutes. His neurologic 
examination was unremarkable at time of presentation. 
His non contrast CT scan of head was unremarkable. 
His ultrasound Doppler of carotids and ECG were 
unremarkable. MR or CT angiogram was not done. His 
HbA1c was normal and lipid profile showed high LDL. 
His echo showed Patent Foramen Ovale. He was 
treated with dual antiplatelet therapy, statin and 
anti-hypertensive medication. 2 weeks later, he 
underwent percutaneous PFO closure and was kept on 
dual antiplatelet therapy for 6 months then switched to 
clopidogrel. He was followed up in clinic for 24 months 
without any complication. 
Figure 1. a) Diffusion weighted imaging (DWI) and 
adjusted Diffusion Coefficient (ADC) of case 1, showing 
acute infraction of right thalamo-capsular junction/ b) 
Diffusion weighted imaging (DWI) and adjusted 
diffusion coefficient (ADC) of case 2, showing acute 
infraction of right periventricular region. c) Diffusion 
weighted imaging (DWI) and adjusted diffusion 
coefficient (ADC) of caes 3, shwoing acute infraction of 
posterior limb of left internal capsule.
Discussion
Cryptogenic strokes comprise one fourth of all ischemic 
strokes and most of them are embolic in nature. 
Case-control studies have demonstrated that PFO is 
more frequent in subjects with cryptogenic cerebral 
infarction than in age-matched subjects without 
cerebral infarction.1 The foramen ovale is passage that 
exists in the wall between the two atria of every human 
fetus. It normally shuts during infancy but in 
approximately one quarter of general population it 
remains patent2.In an autopsy based study, overall 
incidence of PFO was 27%  and incidence decreased 
with increasing age whereas size of defect increased 
with increased age.3In population based study 
Meissner et al have reported that 24.3% of their 
sample population had PFO.4 The correlation of PFO 
with stroke was first described by Cohnheim in year 
1877.5Meta-analysis of case-control studies has 
demonstrated that likelihood of finding PFO was twice 
in subjects with cerebral infarction as compared to 
control subjects and this association was three times 
more likely in group of subjects with cryptogenic 
cerebral infarction whose ages  were less than 55 
years.6Similar findings have been reported in another 
meta-analysis of case-control studies demonstrating 
that likelihood of finding PFO in patients with stroke of 
unknown etiology was three times higher as compared 
to age matched control subjects and it increased to 
fivefold in patients of young age group with cryptogenic 
cerebral infarction.7 Prevalence of PFO in subjects with 
cryptogenic stroke reaches up to 34% to 40%.7,8 
Annual  risk of stroke recurrence in patients with PFO 
has been reported to be ranging from 2% over three 
year follow up duration to as high as 12.5% at 3 years 
follow up in high risk patients.9-13 Two possible 
mechanisms have been hypothesized by which PFO can 
cause stroke, one is susceptibility of such patients to 
atrial arrhythmias with thrombus formation and other is 
paradoxical embolization.14 Likelihood that PFO can be 
cause of stroke increases as patient’s age decreases 
as well as if conventional risk factors for stroke are 
absent.15 Younger patients in whom usual risk factors 
for stroke are not found, such subjects are much more 
likely to have PFO than those patients with usual risk 
factors. Kent at al suggested 10-point Risk of 
Paradoxical Embolism score (RoPE score) to divide 
patients with cryptogenic stroke and PFO into high or 
low likelihood proposing that PFO can be cause of 
stroke or is incidental finding.16 This score uses 
patient’s age, cortical infarction on neuroimaging and 
conventional risk factors of stroke. Higher the RopE 
score, higher likelihood that PFO can be cause of 
stroke. Increased use of saline contrast TEE has 
increased the frequency of detection of PFO in stroke 
patients.Three randomized trials published previously 
addressing hypothesis that PFO closure is better than 
medical therapy in secondary stroke prevention came 
out to be negative.17-19 However, recently published 
three randomized trials addressing similar question 
came out to be positive demonstrating that PFO closure 
is better than medical therapy for secondary stroke 
prevention in patients with stroke of unknown etiology 
and PFO. In a randomized, multicentre trial PFO closure 
along with antiplatelet therapy was found to be 
significantly better for secondary stroke prevention in 
patients with stroke whose stroke was attributed to PFO 
with atrial septal aneurysm or large inter-atrial shunt as 
compared to antiplatelet therapy alone(Hazard 
ratio,0.03;95% confidence interval,0-0.26; 
P<0.001).20Also,in extended follow up for a median 
of 6 years of RESPECT trial cases, recurrence of 
cerebral infarction  was 45% less in patients with 
cryptogenic stroke and PFO for whom PFO closure was 
performed.21 REDUCE trial showed that patients with 
cryptogenic stroke with PFO who underwent FO closure 
had 67% lower risk of recurrent ischemic stroke during 
a median follow up of 3.2 years (HR 0.23%, 95% CI 
0.09 to 0.62; P=0.002).22 All of our cases were less 
than 45 years of age and their routine stroke work up 
including CT/MR angiogram of head and neck, 24 hour 
holter monitor as well as work up for thrombophilia and 
autoimmune diseases was negative. This fits into 
description of cryptogenic stroke. Their 
echocardiograms showed patent formen ovale. As 
discussed above, there is strong association of PFO 
with stroke in such patient population. Therefore, in our 
cases PFO can be considered as likely source of stroke. 
So, PFO closure was performed for our cases for 
secondary stroke prevention. All our cases received 
medical therapy along with PFO closure as was done in 
recently published randomized trials of PFO closure. 
None of our cases had either procedure related 
complication or recurrence of stroke symptoms during 
follow up period ranging from 12 months to 24 months.
 
Conclusion
Patent foramen ovale can be a cause of stroke in young 
patients in whom no other cause of stroke can be found 
on work up. Recent literature has shown efficacy of PFO 
closure in such patient population. Our cases also 
demonstrate that PFO closure can be considered in 
young patients with cryptogenic stroke for secondary 
prevention of stroke.
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